Abstract:Objectives: To develop and validate predictive models for esophageal squamous cell carcinoma (ESCC) using circulating cell-free DNA (cfDNA) terminal motif analysis. The goal was to improve the non-invasive detection of early-stage ESCC and its precancerous lesions. Methods: Between August 2021 and November 2022, we prospectively collected plasma samples from 448 individuals at the Department of Endoscopy, Cancer Hospital, Chinese Academy of Medical Sciences for cfDNA extraction, library construction, and sequencing. We analyzed 201 cases of ESCC, 46 high-grade intraepithelial neoplasia (HGIN), 46 low-grade intraepithelial neoplasia (LGIN), 176 benign esophageal lesions, and 29 healthy controls. Participants, including ESCC patients and control subjects, were randomly assigned to a training set (n=284) and a validation set (n=122). The training cohort underwent z-score normalization of cfDNA terminal motif matrices and a selection of distinctive features differentiated ESCC cases from controls. The random forest classifier, Motif-1 (M1), was then developed through principal component analysis, ten-fold cross-validation, and recursive feature elimination. M1's efficacy was then validated in the validation and precancerous lesion sets. Subsequently, individuals with precancerous lesions were included in the dataset and participants were randomly allocated to newly formed training (n=243), validation (n=105), and test (n=150) cohorts. Using the same procedure as M1, we trained the Motif-2 (M2) random forest model with the training cohort. The M2 model's accuracy was then confirmed in the validation cohort to establish the optimal threshold and further tested by performing validation in the test cohort. Results: We developed two cfDNA terminal motif-based predictive models for ESCC and associated precancerous conditions. The first model, M1, achieved a sensitivity of 90.0%, a specificity of 77.4%, and an area under the curve (AUC) of 0.884 in the validation cohort. For LGIN, HGIN, and T1aN0 stage ESCC, M1's sensitivities were 76.1%, 80.4%, and 91.2% respectively. Notably, the sensitivity for jointly predicting HGIN and T1aN0 ESCC reached 85.0%. Both the predictive accuracy and sensitivity increased in line with the cancer's progression (P＜0.001). The second model, M2, exhibited a sensitivity of 87.5%, a specificity of 77.4%, and an AUC of 0.857 in the test cohort. M2's sensitivities for detecting precancerous lesions and ESCC were 80.0% and 89.7%, respectively, and it showed a combined sensitivity of 89.4% for HGIN and T1aN0 stage ESCC. Conclusions: Two predictive models based on cfDNA terminal motif analysis for ESCC and its precancerous lesions are developed. They both show high sensitivity and specificity in identifying ESCC and its precancerous stages, indicating its potential for early ESCC detection.

Analysis of serum proteomic pattern between patients with esophageal cancer and precancerous lesions in high risk area

Proteomic Diagnosis Models from Serum for Early Detection of Oral Squamous Cell Carcinoma.

[Application of Saliva Protein Fingerprints in the Diagnosis of Oral Squamous Cell Cancer by Surface Enhanced Laser Desorption Ionization Time of Flight Mass].

Combining Proteomics, Serum Biomarkers and Bioinformatics to Discriminate Between Esophageal Squamous Cell Carcinoma and Pre-Cancerous Lesion

[Serum Proteomic Profiles of the Subjects with Esophageal Precancerous and Cancerous Lesions from Linzhou, an Area with High Incidence of Esophageal Cancer in Henan Province, Northern China].

Serum Peptidome Patterns for Early Screening of Esophageal Squamous Cell Carcinoma

Discovery and Validation of Combined Biomarkers for the Diagnosis of Esophageal Intraepithelial Neoplasia and Esophageal Squamous Cell Carcinoma

[Development and Validation of Predictive Models for Esophageal Squamous Cell Carcinoma and Its Precancerous Lesions Using Terminal Motif Analysis in Circulating Cell-Free DNA].

Targeted proteomics-derived biomarker profile develops a multi-protein classifier in liquid biopsies for early detection of esophageal squamous cell carcinoma from a population-based case-control study

Comparative Proteomic Analysis of Esophageal Squamous Cell Carcinoma

Tubulin beta chain, filamin A alpha isoform 1, and cytochrome b-c1 complex subunit 1 as serological diagnostic biomarkers of esophageal squamous cell carcinoma: a proteomics study

Proteomic Analysis on Esophageal Cancer with Lymph Node Metastasis

Proteomics Studies in Esophageal Squamous Cell Carcinoma

Application of SELDI-TOF MS Spectrometry in Serological Diagnosis for Esophageal Squamous Cell Carcinoma

Title Comparative proteomic analysis of esophageal squamous cellcarcinoma

New Metabolic Alterations and A Predictive Marker Pipecolic Acid in Sera for Esophageal Squamous Cell Carcinoma

Preliminary study on proteomics of gastric carcinoma and its clinical significance.

Serum Metabolomic Profiling Reveals Biomarkers for Early Detection and Prognosis of Esophageal Squamous Cell Carcinoma

Preliminary Study of Serum Proteome Biomarkers of Hypopharyngeal Squamous Cell Carcinoma

Proteomic identification of malignant transformation-related proteins in esophageal squamous cell carcinoma

Detection of Hypopharyngeal Squamous Cell Carcinoma Using Serum Proteomics.